BR112022011919A2 - Triterpenoides sintéticos com substituintes à base de nitrogênio em c-17 e métodos de uso dos mesmos - Google Patents
Triterpenoides sintéticos com substituintes à base de nitrogênio em c-17 e métodos de uso dos mesmosInfo
- Publication number
- BR112022011919A2 BR112022011919A2 BR112022011919A BR112022011919A BR112022011919A2 BR 112022011919 A2 BR112022011919 A2 BR 112022011919A2 BR 112022011919 A BR112022011919 A BR 112022011919A BR 112022011919 A BR112022011919 A BR 112022011919A BR 112022011919 A2 BR112022011919 A2 BR 112022011919A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- nitrogen
- based substituents
- aspects
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
TRITERPENOIDES SINTÉTICOS COM SUBSTITUINTES À BASE DE NITROGÊNIO EM C-17 E MÉTODOS DE USO DOS MESMOS. Em alguns aspectos, a presente invenção refere-se a compostos da fórmula: (I) e (II), em que as variáveis são aqui definidas. Também são providas composições farmacêuticas dos mesmos. Em alguns aspectos, os compostos e composições aqui providos podem ser usados como moduladores de inflamação antioxidantes. Em alguns aspectos, a presente invenção refere-se a métodos em que os compostos e a composição aqui descritos são usados para o tratamento de doenças e distúrbios associados a inflamação e câncer.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950927P | 2019-12-19 | 2019-12-19 | |
| US201962950919P | 2019-12-19 | 2019-12-19 | |
| US202063198310P | 2020-10-09 | 2020-10-09 | |
| PCT/US2020/066073 WO2021127480A1 (en) | 2019-12-19 | 2020-12-18 | Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022011919A2 true BR112022011919A2 (pt) | 2022-09-06 |
Family
ID=74554207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022011919A BR112022011919A2 (pt) | 2019-12-19 | 2020-12-18 | Triterpenoides sintéticos com substituintes à base de nitrogênio em c-17 e métodos de uso dos mesmos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230111914A1 (pt) |
| EP (1) | EP4077347A1 (pt) |
| JP (1) | JP2023507402A (pt) |
| KR (1) | KR20220116209A (pt) |
| CN (1) | CN115087660A (pt) |
| AU (1) | AU2020405181A1 (pt) |
| BR (1) | BR112022011919A2 (pt) |
| CA (1) | CA3159778A1 (pt) |
| CL (1) | CL2022001661A1 (pt) |
| CO (1) | CO2022010070A2 (pt) |
| CR (1) | CR20220345A (pt) |
| DO (1) | DOP2022000127A (pt) |
| EC (1) | ECSP22055210A (pt) |
| IL (1) | IL293876A (pt) |
| MX (1) | MX2022007595A (pt) |
| PE (1) | PE20221662A1 (pt) |
| TW (1) | TW202135828A (pt) |
| WO (1) | WO2021127480A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4259155A1 (en) * | 2020-12-11 | 2023-10-18 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ588710A (en) * | 2008-04-18 | 2012-12-21 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
| CN104250280A (zh) * | 2008-04-18 | 2014-12-31 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物 |
| WO2009129545A1 (en) * | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
| UY35534A (es) * | 2013-04-24 | 2014-10-31 | Abbvie Inc | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso |
| WO2020068689A1 (en) * | 2018-09-28 | 2020-04-02 | Fronthera U.S. Pharmaceuticals Llc | Terpinoid derivatives and uses thereof |
-
2020
- 2020-12-18 EP EP20851264.0A patent/EP4077347A1/en active Pending
- 2020-12-18 AU AU2020405181A patent/AU2020405181A1/en active Pending
- 2020-12-18 MX MX2022007595A patent/MX2022007595A/es unknown
- 2020-12-18 TW TW109145170A patent/TW202135828A/zh unknown
- 2020-12-18 KR KR1020227023129A patent/KR20220116209A/ko active Search and Examination
- 2020-12-18 IL IL293876A patent/IL293876A/en unknown
- 2020-12-18 WO PCT/US2020/066073 patent/WO2021127480A1/en active Application Filing
- 2020-12-18 CA CA3159778A patent/CA3159778A1/en active Pending
- 2020-12-18 CR CR20220345A patent/CR20220345A/es unknown
- 2020-12-18 JP JP2022537305A patent/JP2023507402A/ja active Pending
- 2020-12-18 CN CN202080096545.0A patent/CN115087660A/zh active Pending
- 2020-12-18 PE PE2022001140A patent/PE20221662A1/es unknown
- 2020-12-18 BR BR112022011919A patent/BR112022011919A2/pt unknown
- 2020-12-18 US US17/757,701 patent/US20230111914A1/en active Pending
-
2022
- 2022-06-17 DO DO2022000127A patent/DOP2022000127A/es unknown
- 2022-06-17 CL CL2022001661A patent/CL2022001661A1/es unknown
- 2022-07-15 EC ECSENADI202255210A patent/ECSP22055210A/es unknown
- 2022-07-18 CO CONC2022/0010070A patent/CO2022010070A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115087660A (zh) | 2022-09-20 |
| ECSP22055210A (es) | 2022-08-31 |
| CO2022010070A2 (es) | 2022-08-09 |
| JP2023507402A (ja) | 2023-02-22 |
| AU2020405181A1 (en) | 2022-07-14 |
| PE20221662A1 (es) | 2022-10-26 |
| WO2021127480A1 (en) | 2021-06-24 |
| US20230111914A1 (en) | 2023-04-13 |
| MX2022007595A (es) | 2022-07-19 |
| DOP2022000127A (es) | 2022-09-15 |
| IL293876A (en) | 2022-08-01 |
| EP4077347A1 (en) | 2022-10-26 |
| KR20220116209A (ko) | 2022-08-22 |
| CR20220345A (es) | 2023-01-12 |
| TW202135828A (zh) | 2021-10-01 |
| CL2022001661A1 (es) | 2023-01-27 |
| CA3159778A1 (en) | 2021-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020005887A2 (es) | Compuestos policíclicos como inhibidores alostéricos de shp2 | |
| BR112021024674A2 (pt) | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| BR112022002442A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| BR112021022897A2 (pt) | Inibidor contendo derivado bicíclico, método de preparação do mesmo e uso do mesmo | |
| BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
| BR112015023760A2 (pt) | compostos e composições terapêuticas | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| BR112015030385A8 (pt) | composto, composto para uso e composição farmacêutica | |
| BR112019021867A2 (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil | |
| BR112023006024A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| BR112021018924A2 (pt) | Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento | |
| DOP2017000244A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap) | |
| MX370586B (es) | Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes. | |
| BR112018016133A2 (pt) | aglutinantes de max como moduladores de myc e usos dos mesmos | |
| BR112022013322A2 (pt) | Derivado de tetra-hidroisoquinolina tricíclico, método de preparação para o mesmo e aplicação do mesmo em medicina | |
| CO2024005925A2 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| BR112021017957A2 (pt) | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo | |
| BR112022011919A2 (pt) | Triterpenoides sintéticos com substituintes à base de nitrogênio em c-17 e métodos de uso dos mesmos | |
| BR112015014367A2 (pt) | formulações inibidoras de lfa-1 | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 |